[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"late-effect\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:late-effect":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,47,73,97,127],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100624367","neurocognitive-deficit-after-paediatric-transplantation-understanding-the-role-of-environment-and-physical-function-100624367",false,"NCT07408713","Neurocognitive Deficit After Paediatric Transplantation: Understanding the Role of Environment and Physical Function","The NATURE Study (Neurocognitive Deficit After Paediatric Transplantation: Understanding the Role of Environment and Physical Function)","NATURE","Inclusion Criteria:\n\n1. Recipient of allogeneic HSCT in the study period\n2. HSCT at the pediatric ward\n3. Age \\\u003C18 years at referral to HSCT\n4. Signed informed consent\n\nExclusion Criteria:\n\n1\\) Inability of legal guardian to speak and understand Danish","ALL","0 Years","18 Years",{"count":21,"type":22},100,"ESTIMATED","OBSERVATIONAL","Hematopoietic stem cell transplantation (HSCT) is a potentially life-saving treatment for children with relapsed or resistant leukemia and other life-threatening hematological and hereditary disorders. In Denmark, around 25 children undergo allogeneic HSCT every year, of these approximately 85-90% survive into adulthood.\n\nThe goal of this observational study is to learn about neurocognitive outcomes in children undergoing (HSCT) and to understand which clinical, physical, and environmental factors may affect neurocognitive development during the first year after transplant. The main questions it aims to answer are:\n\nHow does neurocognitive function change from before HSCT to one year after transplantation in pediatric patients?\n\nWhich clinical, physical, and environmental factors are linked to better or worse neurocognitive outcomes?\n\nParticipants will:\n\nComplete neurocognitive tests before HSCT and at 1-year follow-up, covering intelligence, memory, attention, executive function, processing speed, and motor skills.\n\nUndergo physical tests before HSCT, at hospital discharge, at 6-months follow-up, and at 1-year follow-up, including muscle strength, mobility, endurance, balance, and cardiopulmonary fitness (only at 1-year follow-up).\n\nWear activity trackers to measure physical activity and sedentary time during hospitalization at 6 months and 1-year post-HSCT.\n\nComplete questionnaires about sleep, pain, quality of life, fatigue, family background, and exposure to outdoor and green spaces.\n\nHave medical records reviewed for treatment-related side effects, immune recovery, inflammation, and pain management.\n\nThis study will help understand how neurocognitive function develops after HSCT in children and which factors (clinical, physical, or environmental) may support better recovery and well-being.",[26,27,28,29,30,31,32,33],"HSCT","Pediatric Cancer","Pediatric Patients","Late Effect","Toxicity","Neurocognitive Dysfunction","Physical Function","Physical Capacity","NOT_YET_RECRUITING","2026-02-18",{"date":37,"type":38},"2026-02-20","ACTUAL",{"date":40,"type":22},"2026-02-15",{"date":42,"type":22},"2031-12-31",{"name":44,"class":45},"Rigshospitalet, Denmark","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":72},"100418711","the-swiss-childhood-cancer-survivor-study---follow-up-sccss-followup-100418711","NCT04732273","The Swiss Childhood Cancer Survivor Study - Follow-up (SCCSS-FollowUp)","SCCSS-FU","This prospective cohort study is based on the Childhood Cancer Registry (ChCR), a national, population-based cancer registry that includes all children and adolescents in Switzerland who were diagnosed with cancer at age 0-20 years. It includes patients diagnosed with leukemia, lymphoma, central nervous system tumors, and malignant solid tumors or Langerhans cell histiocytosis.\n\nInclusion Criteria:\n\n* Registered in the Childhood Cancer Registry (ChCR) or treated and followed-up in a Swiss pediatric oncology (SPOG) clinic, but not registered in the ChCR because of residency in neighboring countries\n* Diagnosed at age 0 - 20 years\n* Childhood cancer treatment completed\n* All age categories at time of inclusion in the study (children, adolescents, adults)\n* Written informed consent\n\nExclusion criteria:\n\n* Childhood cancer survivors in a palliative or relapsed situation where no follow-up examinations are foreseen.",{"count":55,"type":22},3000,"The SCCSS-FollowUp is a national, multicenter cohort study designed to investigate late effects in childhood cancer survivors in a prospective and longitudinal way. The study is embedded in regular follow-up care and inclusion in the study takes place in a step-wise approach. The investigators collect data from clinical examinations, laboratory and functional tests, and questionnaires to learn more about late effects of childhood cancer treatments.",[29,58],"Childhood Cancer",[58,60,61],"Late Effects","Survivor","RECRUITING","2025-09-18",{"date":65,"type":38},"2025-09-23",{"date":67,"type":38},"2022-06-20",{"date":69,"type":22},"2071-01-01",{"name":71,"class":45},"University of Bern",3,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":17,"minAge":81,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":84,"conditions":85,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":46},"100603740","monitoring-neurocognitive-dysfunction-and-the-impact-of-metabolism-and-physical-capacity-after-paediatric-hsct-100603740","NCT07140445","Monitoring Neurocognitive Dysfunction and the Impact of Metabolism and Physical Capacity After Paediatric HSCT","Monitoring Neurocognitive Dysfunction and the Impact of Metabolism and Physical Capacity After Paediatric Haematopoietic Stem Cell Transplantation (Abbreviation: MindMe)","MindMe","Inclusion Criteria:\n\n* =\u002F\\> 7 years of age\n* treatment with HSCT in Denmark since 2010\n* treatment with HSCT was before the age of 18 years\n* ability to speak and understand Danish.\n\nExclusion Criteria:\n\n* diagnosed with infantile autism before their HSCT\n* Downs Syndrome","7 Years",{"count":83,"type":22},175,"Today the overall survival of childhood cancers has increased to above 85%. This increase is partially caused by treatment with bone marrow transplantation. A bone marrow transplantation is an efficient treatment against high-risk leukemia, as well as other life-threatening immunological and hematological diseases. However, it is unfortunately also related to the risk of developing a long series of late effects during early adulthood, such as reduced muscle mass, cardiovascular disease and diabetes.\n\nSome survivors of bone marrow transplantation in childhood also seem to experience changes in cognitive functions. These changes may be experienced as difficulties with concentration, forgetfulness, learning difficulties, and challenges in school or the labour market. Currently, the extent of cognitive changes following bone marrow transplantation in childhood is not fully understood, nor how it relates to other late effects, and what can be done to prevent cognitive impairment.\n\nThis research project will examine cognitive function in a group of survivors of bone marrow transplantation in childhood and find out whether there is a correlation between reduced cognitive function and the occurrence of other late effects, including metabolic changes and reduced physical capacity. It will also explore associations between cognitive function at late follow up and blood-based biomarkers of neurological damage and systemic inflammation at the time of transplantation to identify predictors of reduced cognitive function.\n\nThe goal of the study is to evaluate the level of cognitive functioning after bone marrow transplantation in childhood, see how it relates to other late effect and identify risk factors and biomarkers in the blood that can predict which patients are at risk of neurocognitive impairment. The results of this study will hopefully contribute to optimizing the prevention and treatment of cognitive impairments following bone marrow transplantation in childhood, thereby improving the quality of life for survivors of bone marrow transplantation in childhood.",[86,29,31,87,88,33],"Stem Cell Transplant","Paediatric Patients","Metabolic Syndrome","2025-08-27",{"date":91,"type":38},"2025-09-04",{"date":93,"type":22},"2025-09-01",{"date":95,"type":22},"2027-03-01",{"name":44,"class":45},{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":4,"eligibilityCriteria":103,"healthyVolunteers":11,"sex":104,"minAge":19,"maxAge":105,"enrollmentInfo":106,"targetDuration":108,"studyType":23,"phases":4,"briefSummary":109,"conditions":110,"keywords":113,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":46},"100561231","testicular-function-and-semen-quality-in-male-childhood-and-adolescent-cancer-survivors-100561231","NCT06587477","Testicular Function and Semen Quality in Male Childhood and Adolescent Cancer Survivors","Effect of Cancer Treatment on Testicular Function and Semen Quality in Male Childhood and Adolescent Cancer Survivors","Inclusion Criteria:\n\n* Men who have received chemotherapy and\u002F or radiotherapy for cancer diagnosed when they were \\\u003C 18 years old.\n* \\> 18 years old to 50 years old\n* Cancer in remission for at least 2 years\n\nExclusion Criteria:\n\n* Unable to ejaculate by masturbation to provide semen samples\n* Cryptorchidism, testicular cancer, history of vasectomy\n* On testosterone replacement therapy\n* Refusal to join the study","MALE","50 Years",{"count":107,"type":22},200,"3 Weeks","Cancer treatment can affect the testicular function, including sperm and hormonal functions. The aim of this study is to assess the testicular function and semen quality in young men who recover from childhood and adolescent cancer in Hong Kong. This can provide more information for pre-treatment counselling as well as improve post treatment survivorship care. The testicular function will be compared to aged-matched controls from men attending the Family Planning Association for premarital check-up.",[111,29,112],"Cancer, Treatment-Related","Semen Analysis",[114,115,116,117],"cancer treatment","testicular function","semen quality","cancer survivors","2024-09-06",{"date":120,"type":38},"2024-09-19",{"date":122,"type":38},"2023-01-16",{"date":124,"type":22},"2028-06-30",{"name":126,"class":45},"The University of Hong Kong",{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":131,"acronym":132,"eligibilityCriteria":133,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":134,"enrollmentInfo":135,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":137,"conditions":138,"keywords":140,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":46},"100416411","genetic-risks-for-childhood-cancer-complications-in-switzerland-100416411","NCT04702321","Genetic Risks for Childhood Cancer Complications in Switzerland","GECCOS","Inclusion Criteria:\n\n1. Registered in the Swiss Childhood Cancer Registry (SCCR) since 1976; AND\n2. consented to the BaHOP (host biobank for the BISKIDS Biobanking project); AND\n3. diagnosed with cancer according to the International Classification of Childhood Cancer, version 3, ICCC-3, or Langerhans cell histiocytosis (LCH) before age 21 years.\n\nExclusion Criteria:\n\n1. Lacking written consent signed by participant and\u002F or their legal representative to participate in the BaHOP (where applicable); OR\n2. died after study participation and declined use of their samples and data after their death in the original consent for BaHOP (as indicated on the BaHOP consent).","21 Years",{"count":136,"type":22},6000,"The objectives of the GECCOS project are to identify genetic variants associated with complications of childhood cancer using genotype-phenotype association studies. Germline genetic samples and data of the \"Germline DNA Biobank for Childhood Cancer and Blood Disorders Switzerland\" (BISKIDS) which is included in the Geneva Biobank for Hematology and Oncology in Pediatrics (BaHOP) will be used with clinical data of Swiss childhood cancer patients collected at the Institute of Social and Preventive Medicine in Bern.",[58,139,29],"Genetic Predisposition",[141,142,143,144,145,146,147,148,149,150],"Childhood cancer","Late effects","Therapy complications","Second neoplasm","Registry","Biobank","Genetic variation","Genetic polymorphism","Pharmacogenetics","Genetic association studies","2021-01-11",{"date":153,"type":38},"2021-01-13",{"date":155,"type":38},"2020-12-01",{"date":157,"type":22},"2037-12-31",{"name":159,"class":45},"University Hospital, Geneva"]